Arabic Arabic English English French French German German
dark

Assessment of Extractables/Leachables Data in ANDA Submissions

FDA discusses common review issues encountered in ANDA applications on extractables/leachables studies, the kind of information FDA is looking for and how the FDA evaluates extractables/leachables data in ANDA applications.
Presenters:
Patricia Onyimba, MS
Branch Chief
Division of Liquid-Base Products I, OPQ | CDER

Kshitij (Kris) Patkar, PhD
Senior Pharmaceutical Quality Assessor
Office Pharmaceutical Manufacturing Assessment, OPQ | CDER

Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021
——————– 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training – https://www.fda.gov/cdersbia   
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist – https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance  
SBIA Training Resources – https://www.fda.gov/cderbsbialearn  
Twitter – https://twitter.com/FDA_Drug_Info  
Email – CDERSBIA@fda.hhs.gov  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Biopharmaceutics Risk Assessment to Guide Dissolution Method Development for Solid Oral Dosage Forms

Next Post

Integrated Manufacturing Assessment: Expectations

Related Posts

Panel Discussion

Sarah Ibrahim, Nilufer Tampal, Makini Cobourne-Duval, and Victoria Keck discuss audience questions. Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/generic-drugs-forum-2021-lifecycle-generic-drug-04282021-04292021 ——————–  FDA…
Read More
Total
0
Share